ClinicalTrials.gg
CompletedNCT00844649Updated Nov 25, 2019Results posted

Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas

A Phase 3 interventional study of Albumin-bound paclitaxel (ABI-007) and Gemcitabine in Metastatic Pancreatic Cancer, sponsored by Celgene. Completed at 193 sites in 11 countries. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2019-11-25.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
861
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 130 studies testing Albumin-Bound Paclitaxel in Pancreatic Neoplasms — 22 open to participants now, 33 under way, 4 of them phase 3. Albumin-Bound Paclitaxel · Pancreatic Neoplasms.

Enrollment
5th of 130
861 · median 47
Started
2009
the only one that year
Phase 3
8 of 130
4 open now
Registered
3rd of 130
by date
Lead sponsor
8 of 130
Celgene

Among the 130 studies testing Albumin-Bound Paclitaxel in Pancreatic Neoplasms, this one is the 5th largest by enrollment, is the only one that started in 2009, is one of 8 in phase 3, and was the 3rd registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,003 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

22 of the 130 studies testing Albumin-Bound Paclitaxel in Pancreatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About Albumin-Bound Paclitaxel

Albumin-Bound Paclitaxel: first FDA approval 2005 (ABRAXANE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 477 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies testing Albumin-Bound Paclitaxel in Pancreatic Neoplasms, or all of them as a file.
02

Study summary

Phase III Metastatic Pancreatic Cancer

Read the detailed description

A Phase III, open-label randomized, multicenter trial to compare ABI-007(Albumin-bound Paclitaxel)in combination with gemcitabine administered weekly to standard treatment (gemcitabine monotherapy) with respect to overall survival, objective tumor response rate and Progression Free Survival (PFS) in patients diagnosed with metastatic adenocarcinoma of the pancreas.

03

Conditions studied

  • Metastatic Pancreatic Cancer
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A participant will be eligible for inclusion in this study only if all of the following criteria are met:

  1. Participant has definitive or cytologically confirmed adenocarcinoma of the pancreas. The definitive diagnosis of metastatic pancreatic adenocarcinoma will be made by integrating the histopathological data within the context of the clinical and radiographic data. Participants with islet cell neoplasms are excluded.
  2. Initial diagnosis of metastatic disease must have occurred ≤6 weeks prior to randomization in the study.
  3. Patient has one or more metastatic tumors measurable by Computed Tomography (CT) scan or Magnetic resonance imaging (MRI), if patient is allergic to CT contrast media).
  4. Male or non-pregnant and non-lactating female, and ≥ 18 years of age. If a female patient is of , as evidenced by regular menstrual periods, she must have a negative serum pregnancy test Beta-Human Chorionic Gonadotropin (β-hCG) documented 72 hours prior to the first administration of study drug.

    If sexually active, the patient must agree to use considered adequate and appropriate by the Investigator during the period of administration of study drug. In addition, male and female patients must utilize contraception after the end of treatment as recommended in the product's Summary of Product Characteristics or Prescribing Information provided in the study manual.

  5. Patients must have received no previous radiotherapy, surgery, chemotherapy or therapy for the treatment of metastatic disease. Prior treatment with 5-Fluorouracil (5-FU) or gemcitabine administered as a radiation sensitizer in the setting is allowed, provided at least 6 months have elapsed since completion of the last dose and no lingering toxicities are present. Patients having received cytotoxic doses of gemcitabine or any other chemotherapy in the adjuvant setting are not eligible for this study.
  6. Patient has adequate biological parameters as demonstrated by the following blood counts at Baseline (obtained ≤14 days prior to randomization):

    (ANC) ≥ 1.5 × 10\^9/L; count ≥ 100,000/mm\^3 (100 × 10\^9/L); (Hgb) ≥ 9 g/dL.

  7. Patient has the following blood chemistry levels at Baseline (obtained ≤14 days prior to randomization):

    (AST), Serum Glutamic-Oxaloacetic Transaminase (SGOT), Alanine Transaminase ( ALT) Serum Glutamic-Pyruvic Transaminase (SGPT) ≤ 2.5 × (ULN), unless liver metastases are clearly present, then ≤ 5 × ULN is allowed Total ≤ ULN Serum creatinine within normal limits or calculated clearance ≥ 60 mL/min/1.73 m\^2 for patients with serum creatinine levels above or below the institutional normal value. If using , actual body weight should be used for calculating creatinine clearance (e.g., using the Cockroft-Gault formula). For patients with a (BMI) >30 kg/m\^2, lean body weight should be used instead.

  8. Patient has acceptable coagulation studies (obtained ≤14 days prior to randomization) as demonstrated by (PT) and partial thromboplastin time (PTT) within normal limits (± 15%).
  9. Patient has no abnormalities in urinalysis results (obtained ≤14 days prior to randomization).
  10. Patient has a performance status (KPS) ≥ 70. Two observers will be required to assess KPS. If discrepant, the one with the lowest assessment will be considered true.
  11. Patients should be asymptomatic for jaundice prior to Day 1. Significant or symptomatic amounts of ascites should be drained prior to Day 1. Pain symptoms should be stable and should not require modifications in analgesic management prior to Day 1.
  12. Patient has been informed about the nature of the study, and has agreed to participate in the study, and signed the Form (ICF) prior to participation in any study-related activities.

Exclusion criteria

Exclusion Criteria

A patient will not be eligible for inclusion in this study if any of the following criteria apply:

  1. Patient has known , unless previously treated and well-controlled for at least 3 months (defined as clinically stable, no edema, no and stable in 2 scans at least 4 weeks apart).
  2. Patient has only locally advanced disease.
  3. Patient has experienced a ≥10% decrease in between baseline visit and within 72 hours prior to randomization.
  4. Patient has a ≥20% decrease in serum albumin level between baseline visit and within 72 hours prior to randomization.
  5. History of in the last 5 years. Patients with prior history of in situ cancer or basal or squamous cell skin cancer are eligible. Patients with other malignancies are eligible if they were cured by surgery alone or surgery plus radiotherapy and have been continuously disease-free for at least 5 years.
  6. Patient uses Coumadin.
  7. Patient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.
  8. Patient has known historical or active infection with (HIV), , or .
  9. Patient has undergone major surgery, other than diagnostic surgery (i.e.--surgery done to obtain a for diagnosis without removal of an organ), within 4 weeks prior to Day 1 of treatment in this study.
  10. Patient has a history of allergy or to any of the study drugs or any of their , or the patient exhibits any of the events outlined in the or Special Warnings and Precautions sections of the product or comparator Summary of Product Characteristics (SmPC) or Prescribing Information.
  11. History of connective tissue disorders (e.g., lupus, scleroderma, arteritis nodosa).
  12. Patients with a history of interstitial lung disease.
  13. History of chronic leukemias (e.g., chronic lymphocytic leukemia).
  14. Patients with high cardiovascular risk, including, but not limited to, recent coronary stenting or myocardial infarction in the past year.
  15. History of Peripheral Artery Disease (e.g,. claudication, Leo Buerger's disease).
  16. Patient has serious medical risk factors involving any of the major organ systems, or serious psychiatric disorders, which could compromise the patient's safety or the study data integrity.
  17. Patient is enrolled in any other clinical protocol or trial.
  18. Patient is unwilling or unable to comply with study procedures, or is planning to take vacation for 7 or more consecutive days during the course of the study.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
861 participants (actual)

Study arms

  • Experimental
    Albumin-bound paclitaxel (ABI-007)/Gemcitabine

    ABI-007 125 mg/m2 administered in combination with gemcitabine 1000 mg/m2 weekly for 3 weeks followed by one week of rest.

    Drug: Albumin-bound paclitaxel (ABI-007) · Drug: Gemcitabine

  • Active comparator
    Gemcitabine

    Gemcitabine, 1000 mg/m2 administered weekly for 7 weeks followed by a week of rest (Cycle 1), followed by cycles of weekly administration for 3 weeks followed by a week of rest (Cycle 2 onward).

    Drug: Gemcitabine

Interventions

  • ABI-007 125 mg/m\^2 administered by intravenous infusion

    Also known as: Abraxane

  • Gemcitabine, 1000 mg/m2 administered weekly for 7 weeks, Day 1 through Day 43 followed by a week of rest (Cycle 1), followed by cycles of weekly administration for 3 weeks, Days 1, 8, and 15 followed by a week of rest (Cycle 2 onward).

    Also known as: Gemzar

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Overall survival was defined as the time from the date of randomization to the date of death from all causes. Participants who did not die were censored at the last known time the participant was alive. Patient survival was summarized using Kaplan-Meier methods.

    Time frame: From randomization to death; until the data cut off 17 Sept 2012. The maximum time in follow up was 37 months.

Secondary outcomes

  1. Progression-free Survival (PFS) by Independent Radiological Review (IRR)

    Progression-free survival was defined as the time from the date of randomization to the date of disease progression, or death (any cause) on or prior to the clinical cutoff date, whichever occurred earlier. Participants who did not have disease progression or had not died were censored at the date of the last tumor assessment, on or prior to the clinical cutoff, and the patient was progression free. If a patient began a new anti-cancer treatment prior to documented disease progression (or death), the patient was censored at the date of last assessment when the patient was documented as progression free prior to the intervention. Patients with two or more consecutive missing response assessments prior to a visit with documented progression (or death) were censored at the last date of tumor assessment when the patient was documented to be progression free. PFS was summarized using Kaplan-Meier methods.

    Time frame: Randomization until disease progression or death from any cause; Until the data cut off of 17 Sept 2012. The maximum time in follow up was 37 months.

  2. Percentage of Participants Who Achieved an Objective Confirmed Overall Response by Independent Radiological Review (IRR)

    Objective tumor response was summarized as the percentage of participants who achieved a confirmed complete (CR) or partial response (PR) based on an independent blinded radiology assessment of response using Response Evaluation Criteria in Solid Tumors (RECIST) guidelines. Using RECIST Version 1.0, participants were to achieve either a complete response (CR) defined as the disappearance of all known disease and no new sites or disease related symptoms confirmed at least 4 weeks after initial documentation or partial response (PR) defined as at least a 30% decrease in the sum of the longest diameters of target lesions and no progression in non-target lesions based on confirmed responses from the investigator assessment of best overall response during study treatment.

    Time frame: Assessment every 4 weeks after initial response; Day 1 to data cut off of 17 Sept 2013; maximum time on study 37 months

Other outcomes

  1. Participants With Treatment Emergent Adverse Events (AE)

    A Treatment Emergent Adverse Event (TEAE) is as any AE occurring or worsening on or after the first treatment of any study drug, and within 30 days after the last dose of the last study drug. Severity grades according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE) on a 1-5 scale: Grade 1= Mild AE, Grade 2= Moderate AE, Grade 3= Severe AE, Grade 4= Life-threatening or disabling AE, Grade 5=Death related to AE.

    Time frame: Study drug initiation through 30 days after the last dose of study drug or EOS, whichever is later; Up to 696 days

  2. Number of Participants With Dose Reductions

    The number of participants with dose reductions occurring during the treatment period. Dose reductions are typically caused by clinically significant laboratory abnormalities and /or treatment emergent adverse events/toxicities.

    Time frame: Maximum time on treatment was 666 days

  3. Number of Participants With Dose Interruptions

    The number of participants with dose interruptions experienced by participants that occurred during the treatment period. Dose interruptions are typically caused by clinically significant laboratory abnormalities and /or treatment emergent adverse events/toxicities.

    Time frame: Maximum time on treatment was 666 days

  4. Number of Participants With Dose Delays/Doses Not Given

    The number of dose delays or doses not given experienced by participants during the treatment period. Dose delays are typically caused by clinically significant laboratory abnormalities and /or treatment emergent adverse events/toxicities. Treatment delays of no longer than 21 days allowed participants to recover from acute toxicity, otherwise participants were discontinued from further treatment except in the event of peripheral neuropathy.

    Time frame: Up to 666 days

07

Results

Posted Dec 11, 2013

Participant flow

Participants were randomized in a 1:1 ratio and the randomization was stratified by geographic region (Australia versus Eastern Europe versus Western Europe versus North America), Karnofsky performance status (70 to 80 versus 90 to 100), and by the presence of liver metastases (yes versus no)

Participant flow — Overall Study
MilestoneAlbumin-bound Paclitaxel (ABI-007)/Gemcitabine (Gem)Gemcitabine (Gem)
Started431430
Treated population421402
Completed2612
Not completed405418
Withdrew: Progressive disease196245
Withdrew: Adverse event12873
Withdrew: Physician decision2518
Withdrew: Protocol violation106
Withdrew: Withdrawal by subject2839
Withdrew: Other710
Withdrew: Withdrew prior to starting treatment1127

Outcome measures

PrimaryOverall Survival (OS)

Overall survival was defined as the time from the date of randomization to the date of death from all causes. Participants who did not die were censored at the last known time the participant was alive. Patient survival was summarized using Kaplan-Meier methods.

Time frame:
From randomization to death; until the data cut off 17 Sept 2012. The maximum time in follow up was 37 months.
Reported as:
Median · months
Overall Survival (OS)
monthsAlbumin-bound Paclitaxel (ABI-007)/GemcitabineGemcitabine
Overall Survival (OS)8.5 (7.89 to 9.53)6.7 (6.01 to 7.23)
Statistical analysis
  • Albumin-bound Paclitaxel (ABI-007)/Gemcitabine vs Gemcitabine · Stratified Log-rank Test · p = <0.0001 (P-value was based on a stratified log-rank test stratified by randomization strata of geographic region (North America versus Others), Karnofsky performance score (70 to 80 versus 90 to 100), and presence of liver metastasis) · Hazard ratio (hr): 0.72 · 95% CI 0.617 to 0.835Hazard ratio of Albumin bound paclitaxel + gemcitabine/gemcitabine alone. The associated hazard ratio and two-sided 95% confidence interval were estimated using a stratified Cox proportional hazard model.
SecondaryProgression-free Survival (PFS) by Independent Radiological Review (IRR)

Progression-free survival was defined as the time from the date of randomization to the date of disease progression, or death (any cause) on or prior to the clinical cutoff date, whichever occurred earlier. Participants who did not have disease progression or had not died were censored at the date of the last tumor assessment, on or prior to the clinical cutoff, and the patient was progression free. If a patient began a new anti-cancer treatment prior to documented disease progression (or death), the patient was censored at the date of last assessment when the patient was documented as progression free prior to the intervention. Patients with two or more consecutive missing response assessments prior to a visit with documented progression (or death) were censored at the last date of tumor assessment when the patient was documented to be progression free. PFS was summarized using Kaplan-Meier methods.

Time frame:
Randomization until disease progression or death from any cause; Until the data cut off of 17 Sept 2012. The maximum time in follow up was 37 months.
Reported as:
Median · months
Progression-free Survival (PFS) by Independent Radiological Review (IRR)
monthsAlbumin-bound Paclitaxel (ABI-007)/GemcitabineGemcitabine
Progression-free Survival (PFS) by Independent Radiological Review (IRR)5.5 (4.47 to 5.95)3.7 (3.61 to 4.04)
Statistical analysis
  • Albumin-bound Paclitaxel (ABI-007)/Gemcitabine vs Gemcitabine · Stratified Log-rank Test · p = <0.0001 (P-value was based on a stratified log-rank test by randomization strata of geographic region (North America versus Others), Karnofsky performance score (70 to 80 versus 90 to 100), and presence of liver metastasis (yes vs no)) · Hazard ratio (hr): .69 · 95% CI 0.581 to 0.821Hazard ratio of Albumin bound paclitaxel + gemcitabine / gemcitabine alone. The associated hazard ratio and two-sided 95% confidence interval were estimated using a stratified Cox proportional hazard model.
SecondaryPercentage of Participants Who Achieved an Objective Confirmed Overall Response by Independent Radiological Review (IRR)

Objective tumor response was summarized as the percentage of participants who achieved a confirmed complete (CR) or partial response (PR) based on an independent blinded radiology assessment of response using Response Evaluation Criteria in Solid Tumors (RECIST) guidelines. Using RECIST Version 1.0, participants were to achieve either a complete response (CR) defined as the disappearance of all known disease and no new sites or disease related symptoms confirmed at least 4 weeks after initial documentation or partial response (PR) defined as at least a 30% decrease in the sum of the longest diameters of target lesions and no progression in non-target lesions based on confirmed responses from the investigator assessment of best overall response during study treatment.

Time frame:
Assessment every 4 weeks after initial response; Day 1 to data cut off of 17 Sept 2013; maximum time on study 37 months
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an Objective Confirmed Overall Response by Independent Radiological Review (IRR)
percentage of participantsAlbumin-bound Paclitaxel (ABI-007)/GemcitabineGemcitabine
Percentage of Participants Who Achieved an Objective Confirmed Overall Response by Independent Radiological Review (IRR)23 (19.1 to 27.2)7 (5.0 to 10.1)
Statistical analysis
  • Albumin-bound Paclitaxel (ABI-007)/Gemcitabine vs Gemcitabine · Chi-squared · p = <0.0001 · Response rate ratio: 3.19 · 95% CI 2.178 to 4.662Response rate ratio: albumin-bound paclitaxel + gemcitabine /gemcitabine alone
Other pre-specifiedParticipants With Treatment Emergent Adverse Events (AE)

A Treatment Emergent Adverse Event (TEAE) is as any AE occurring or worsening on or after the first treatment of any study drug, and within 30 days after the last dose of the last study drug. Severity grades according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE) on a 1-5 scale: Grade 1= Mild AE, Grade 2= Moderate AE, Grade 3= Severe AE, Grade 4= Life-threatening or disabling AE, Grade 5=Death related to AE.

Time frame:
Study drug initiation through 30 days after the last dose of study drug or EOS, whichever is later; Up to 696 days
Reported as:
Number · participants
Participants With Treatment Emergent Adverse Events (AE)
participantsAlbumin-bound Paclitaxel (ABI-007)/GemcitabineGemcitabine
At least 1 AE417395
≥ 1 Treatment related AE (TEAE)403371
At least 1 Serious Adverse Event (SAE)212172
≥ 1 treatment related SAE12153
≥ 1 Grade (GR) 3/4 AE370298
≥ 1 Grade 3 or higher AE374303
≥ 1 AE leading to stopping treatment14995
≥ 1 AE leading to death1818
≥ 1 AE leading to dose reduction of ABI-007 or Gem209125
≥ 1 AE related dose interruption of ABI-007 or Gem1110
≥ 1 AE related dose delay of ABI-007 or Gem276192
Other pre-specifiedNumber of Participants With Dose Reductions

The number of participants with dose reductions occurring during the treatment period. Dose reductions are typically caused by clinically significant laboratory abnormalities and /or treatment emergent adverse events/toxicities.

Time frame:
Maximum time on treatment was 666 days
Reported as:
Number · participants
Number of Participants With Dose Reductions
participantsAlbumin-bound Paclitaxel (ABI-007)/Gemcitabine (Gem)Gemcitabine (Gem)
At least 1 alumbin bound paclitaxel dose reduction1720
At least 1 Gemcitabine dose reduction198132
Other pre-specifiedNumber of Participants With Dose Interruptions

The number of participants with dose interruptions experienced by participants that occurred during the treatment period. Dose interruptions are typically caused by clinically significant laboratory abnormalities and /or treatment emergent adverse events/toxicities.

Time frame:
Maximum time on treatment was 666 days
Reported as:
Number · participants
Number of Participants With Dose Interruptions
participantsAlbumin-bound Paclitaxel (ABI-007)/GemcitabineGemcitabine
≥ 1 Albumin-bound paclitaxel dose interruption20
At least 1 Gemcitabine dose interruption89
Other pre-specifiedNumber of Participants With Dose Delays/Doses Not Given

The number of dose delays or doses not given experienced by participants during the treatment period. Dose delays are typically caused by clinically significant laboratory abnormalities and /or treatment emergent adverse events/toxicities. Treatment delays of no longer than 21 days allowed participants to recover from acute toxicity, otherwise participants were discontinued from further treatment except in the event of peripheral neuropathy.

Time frame:
Up to 666 days
Reported as:
Number · number of dose delays
Number of Participants With Dose Delays/Doses Not Given
number of dose delaysAlbumin-bound Paclitaxel (ABI-007)/GemcitabineGemcitabine
At least 1 ABI-007 dose delay/Not given3000
At least ≥ 1 Gem dose delay/Not given295230

Adverse events

Collected over Day 1 up to 30 days after the last dose (a maximum of 666 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Albumin-bound Paclitaxel (ABI-007)/Gemcitabine—212/421 (50.4%)412/421 (97.9%)
Gemcitabine—172/402 (42.8%)392/402 (97.5%)
Most frequent serious events
Showing 10 of 232
Most frequent serious events
EventAlbumin-bound Paclitaxel (ABI-007)/GemcitabineGemcitabine
PyrexiaGeneral disorders27/4219/402
Pulmonary embolismRespiratory, thoracic and mediastinal disorders13/42120/402
DehyrationMetabolism and nutrition disorders20/42112/402
VomitingGastrointestinal disorders18/42112/402
PneumoniaInfections and infestations17/42111/402
Deep vein thrombosisVascular disorders9/42112/402
Abdominal PainGastrointestinal disorders11/42110/402
NauseaGastrointestinal disorders11/4218/402
Febrile neutropeniaBlood and lymphatic system disorders11/4212/402
CholangitisHepatobiliary disorders10/4215/402
Most frequent other events
Showing 10 of 60
Most frequent other events
EventAlbumin-bound Paclitaxel (ABI-007)/GemcitabineGemcitabine
FatigueGeneral disorders247/421183/402
NauseaGastrointestinal disorders223/421189/402
AlopeciaSkin and subcutaneous tissue disorders212/42121/402
Oedema peripheralGeneral disorders194/421123/402
DiarrhoeaGastrointestinal disorders182/42194/402
AnaemiaBlood and lymphatic system disorders175/421131/402
NeutropeniaBlood and lymphatic system disorders172/421122/402
PyrexiaGeneral disorders160/421111/402
Decreased appetiteMetabolism and nutrition disorders149/421104/402
VomitingGastrointestinal disorders145/421107/402

Baseline characteristics

For the Karnofsky Performance Status (KPS) baseline characteristic, some of the participants did not have a baseline KPS recorded by the clinical site.

Age, Continuous
Age, Continuous(years)Albumin-bound Paclitaxel (ABI-007)/GemcitabineGemcitabineTotal
Mean61.4 ± 10.7063.0 ± 9.2762.2 ± 10.04
Sex: Female, Male
Sex: Female, Male(Participants)Albumin-bound Paclitaxel (ABI-007)/GemcitabineGemcitabineTotal
Female186173359
Male245257502
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Albumin-bound Paclitaxel (ABI-007)/GemcitabineGemcitabineTotal
American Indian or Alaska Native000
Asian8917
Native Hawaiian or Other Pacific Islander101
Black or African American161632
White378375753
More than one race252651
Unknown or Not Reported347
Karnofsky Performance Status (KPS)
Karnofsky Performance Status (KPS)(participants)Albumin-bound Paclitaxel (ABI-007)/GemcitabineGemcitabineTotal
100% = normal, no complaints, no signs of disease6969138
90% = normal activity, few symptoms of disease179199378
80% = normal activity, some symptoms of disease149128277
70% = caring for self, unable to work303363
60% = needs help, can manage most tasks202
50% = needs help often and medical care000
40% = disabled; requires special care & assistance000
30% = severely disabled; death is imminent000
20% = hospitalized; requires supportive treatment000
10% = Moribund, fatal processes progressing fast000
0% = Dead000
Pancreatic Primary Tumor Location
Pancreatic Primary Tumor Location(participants)Albumin-bound Paclitaxel (ABI-007)/GemcitabineGemcitabineTotal
Head191180371
Body132136268
Tail105110215
Unknown = not specified347
Number of Baseline Lesions (Target + Non-Target)
Number of Baseline Lesions (Target + Non-Target)(participants)Albumin-bound Paclitaxel (ABI-007)/GemcitabineGemcitabineTotal
1101
2322557
37714
4374380
58816
>5276262538
08

Study locations

193 sites
  • UAB Comprenhensive Cancer Center at University of Alabama
    Birmingham, Alabama 35294, United States
  • Clearview Cancer Institute Oncology Specialities, P.C.
    Huntsville, Alabama 35805, United States
  • TGEN Clinical Research Services at Scottsdale Healthcare
    Scottsdale, Arizona 85258, United States
  • Mayo Clinic-Scottsdale
    Scottsdale, Arizona 85259, United States
  • Northern Arizona Hematology and Oncology Associates-AOA
    Sedona, Arizona 86336, United States
  • Arizona Cancer Center, University of Arizona
    Tucson, Arizona 85724, United States
  • Genesis Cancer Center
    Hot Springs, Arkansas 71913, United States
  • Tower Cancer Research Foundation
    Beverly Hills, California 90211, United States
  • City of Hope
    Duarte, California 91010, United States
  • Pacific Shores Medical Group
    Long Beach, California 90813, United States
  • UCLA
    Los Angeles, California 90024, United States
  • Desert Hematology Oncology Medical Group, Inc.
    Rancho Mirage, California 92270, United States
  • University of Colorado Cancer Center
    Aurora, Colorado 80045, United States
  • Rocky Mountain Cancer Center
    Denver, Colorado 80218, United States
  • University Cancer Institute, LLC
    Boynton Beach, Florida 33426, United States
  • Collaborative Research Group
    Boynton Beach, Florida 33435, United States
  • FL Cancer Specialist
    Fort Myers, Florida 33916, United States
  • Lakeland Regional Cancer Center
    Lakeland, Florida 33805, United States
  • Ocala Oncology Center
    Ocala, Florida 34471, United States
  • Florida Hospital Cancer Institute
    Orlando, Florida 32804, United States
  • Lake County Oncology and Hematology
    Tavares, Florida 32778, United States
  • Phoebe Putney Cancer Center
    Albany, Georgia 31701, United States
  • Northeast Georgia Cancer Care, LLC
    Athens, Georgia 30607, United States
  • Piedmont Hospital Research Institute
    Atlanta, Georgia 30309, United States
  • Georgia Cancer Specialists
    Atlanta, Georgia 30341, United States
  • Atlanta Cancer Care
    Atlanta, Georgia 30342, United States
  • Cancer Care & Hemaotology Specialists of Chicagoland
    Arlington Heights, Illinois 60005, United States
  • NorthShore University HealthSystem
    Evanston, Illinois 60021, United States
  • Cancer Care & Hematology Specialists of Chicagoland
    Niles, Illinois 60714, United States
  • Illinois Cancer Care
    Peoria, Illinois 61615, United States
  • Orchard Research
    Skokie, Illinois 60076, United States
  • Indiana University Simon Cancer Center
    Indianapolis, Indiana 46202, United States
  • Hutchinson Clinic, PA
    Hutchinson, Kansas 67502, United States
  • Owsley Brown Frazier Cancer Center
    Louisville, Kentucky 40245, United States
  • Hematology Oncology Clinic
    Baton Rouge, Louisiana 70809, United States
  • Mary Bird Perkins Cancer Center
    Baton Rouge, Louisiana 70809, United States
  • Central Maine Medical Center
    Lewiston, Maine 04240, United States
  • Mercy Hospital Portland, ME
    Portland, Maine 04102, United States
  • Maine Center for Cancer Medicine
    Scarborough, Maine 04074, United States
  • Sidney Kimmel Comphrensive Cancer Center, John Hopkins University
    Baltimore, Maryland 21231, United States
  • Center for Cancer & Blood Disorders
    Bethesda, Maryland 20817, United States
  • Lahey Clinic
    Burlington, Massachusetts 01805, United States
  • Cancer Center of Excellence/University of MA Medical School
    Worcester, Massachusetts 01655, United States
  • St. Mary's/ Duluth Clinic
    Duluth, Minnesota 55805, United States
  • Virginia Piper Cancer Institute
    Minneapolis, Minnesota 55408, United States
  • University of Minnesota, Masonic Cancer Center
    Minneapolis, Minnesota 55455, United States
  • Saint Louis University
    Saint Louis, Missouri 63110, United States
  • St. John's Medical Research Institute
    Springfield, Missouri 65807, United States
  • The Center for Cancer and Hematologic Disease
    Cherry Hill, New Jersey 08003, United States
  • Hem Onc Associates-NM
    Albuquerque, New Mexico 87106, United States
  • University of New Mexico
    Albuquerque, New Mexico 87131-0001, United States
  • New York Oncology Hematology PC
    Albany, New York 12206, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Arena Oncology Associates, PC
    Lake Success, New York 11042, United States
  • SUNY Upstate Medical University
    Syracuse, New York 13210, United States
  • Piedmont Hematology Oncology
    Winston-Salem, North Carolina 27103, United States
  • Oncology Hematology Care
    Cincinnati, Ohio 45242, United States
  • Mid Ohio Oncology/Hematology Inc
    Columbus, Ohio 43219, United States
  • Kettering Medical Center
    Kettering, Ohio 45429, United States
  • Signal Point Clinical Research Center, LLC
    Middletown, Ohio 45042, United States
  • Cancer Centers of SW OK
    Lawton, Oklahoma 73505, United States
  • University of Oklahoma Health Science Center
    Oklahoma City, Oklahoma 73104, United States
  • Mercy Physicians of Oklahoma
    Oklahoma City, Oklahoma 73112, United States
  • Cancer Care Associates- Tulsa
    Tulsa, Oklahoma 74104, United States
  • St. Mary Medical Center Hem-Onc Group, PC
    Langhorne, Pennsylvania 19047, United States
  • University of Pittsburg Medical Center
    Pittsburgh, Pennsylvania 15232, United States
  • South Carolina Oncology Associates
    Columbia, South Carolina 29210, United States
  • Chattanooga Oncology Hematology Associates
    Chattanooga, Tennessee 37404, United States
  • Tennessee Oncology
    Nashville, Tennessee 37203, United States
  • Medical City Dallas-US Oncology
    Dallas, Texas 75230-2510, United States
  • Texas Oncology, PA
    Dallas, Texas 75231-4400, United States
  • Texas Oncology, PA/ Methodist Charlton Cancer Center
    Dallas, Texas 75237, United States
  • Texas Oncology Laboratories
    Fort Worth, Texas 76104, United States
  • The Center for Cancer and Blood Disorders
    Fort Worth, Texas 76104, United States
  • The University of Texas Medical School at Houston
    Houston, Texas 77030, United States
  • Texas Oncology- Plano East
    Plano, Texas 75075, United States
  • Texas Oncology, PA
    Round Rock, Texas 76885, United States
  • Texas Oncology-Round Rock
    Round Rock, Texas 78681, United States
  • South Texas Oncology and Hematology, P.A
    San Antonio, Texas 78229, United States
  • Texas Oncology, PA
    Wichita Falls, Texas 76310, United States
  • Utah Cancer Specialists
    Salt Lake City, Utah 84106, United States
  • Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
  • Fairfax-Northern Virginia Hematology-Oncology, P.C.
    Fairfax, Virginia 22031, United States
  • Virginia Cancer Specialist, PC
    Fairfax, Virginia 22031, United States
  • Virginia Cancer Institute
    Richmond, Virginia 23230, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298-0037, United States
  • Swedish Health Services
    Seattle, Washington 98104, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109, United States
  • Evergreen Hematology & Oncology
    Spokane, Washington 99218, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Bankstown-Lidcombe Hospital
    Bankstown, New South Wales 2200, Australia
  • Macarthur Cancer Therapy Center
    Campbelltown, New South Wales 2560, Australia
  • Concord Hospital
    Concord, New South Wales 2139, Australia
  • St. Vincent's Hospital
    Darlinghurst, New South Wales 2010, Australia
  • Prince of Wales Hospital
    Randwick, New South Wales 2031, Australia
  • Newcastle Hospital
    Waratah, New South Wales 2298, Australia
  • Southern Medical Day Care Centre
    Wollongong, New South Wales 2500, Australia
  • Royal Brisbane and Women's Hospital
    Herston, Queensland 4029, Australia
  • Haemotology & Oncology Australasia (HOCA)
    Milton, Queensland 4101, Australia
  • Haematology Oncology Clinics of Australasia-Gold Coast
    Milton, Queensland 4215, Australia

Showing the first 100 of 193 sites across 11 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Tabernero J, Chiorean EG, Infante JR, Hingorani SR, Ganju V, Weekes C, Scheithauer W, Ramanathan RK, Goldstein D, Penenberg DN, Romano A, Ferrara S, Von Hoff DD. Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Oncologist. 2015 Feb;20(2):143-50. doi: 10.1634/theoncologist.2014-0394. Epub 2015 Jan 12. PubMed 25582141 ↗
  • Chiorean EG, Von Hoff DD, Tabernero J, El-Maraghi R, Ma WW, Reni M, Harris M, Whorf R, Liu H, Li JS, Manax V, Romano A, Lu B, Goldstein D. Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer. Br J Cancer. 2016 Jul 12;115(2):188-94. doi: 10.1038/bjc.2016.185. Epub 2016 Jun 28. Erratum In: Br J Cancer. 2016 Oct 25;115(9):e13. doi: 10.1038/bjc.2016.306. PubMed 27351217 ↗
  • Tehfe M, Dowden S, Kennecke H, El-Maraghi R, Lesperance B, Couture F, Letourneau R, Liu H, Romano A. nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial. Adv Ther. 2016 May;33(5):747-59. doi: 10.1007/s12325-016-0327-4. Epub 2016 Apr 16. Erratum In: Adv Ther. 2017 Jan;34(1):277-279. doi: 10.1007/s12325-016-0442-2. PubMed 27085323 ↗
  • Scheithauer W, Ramanathan RK, Moore M, Macarulla T, Goldstein D, Hammel P, Kunzmann V, Liu H, McGovern D, Romano A, Von Hoff DD. Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial. J Gastrointest Oncol. 2016 Jun;7(3):469-78. doi: 10.21037/jgo.2016.01.03. PubMed 27284481 ↗
  • Vogel A, Rommler-Zehrer J, Li JS, McGovern D, Romano A, Stahl M. Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT). BMC Cancer. 2016 Oct 21;16(1):817. doi: 10.1186/s12885-016-2798-8. PubMed 27769210 ↗
  • Kunzmann V, Ramanathan RK, Goldstein D, Liu H, Ferrara S, Lu B, Renschler MF, Von Hoff DD. Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine: An Exploratory Analysis From a Phase 3 Study. Pancreas. 2017 Feb;46(2):203-208. doi: 10.1097/MPA.0000000000000742. PubMed 27841795 ↗
  • Tabernero J, Kunzmann V, Scheithauer W, Reni M, Shiansong Li J, Ferrara S, Djazouli K. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial. Onco Targets Ther. 2017 Feb 2;10:591-596. doi: 10.2147/OTT.S124097. eCollection 2017. PubMed 28203092 ↗
  • Ramanathan RK, Goldstein D, Korn RL, Arena F, Moore M, Siena S, Teixeira L, Tabernero J, Van Laethem JL, Liu H, McGovern D, Lu B, Von Hoff DD. Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas. Ann Oncol. 2016 Apr;27(4):648-53. doi: 10.1093/annonc/mdw020. Epub 2016 Jan 22. PubMed 26802153 ↗
  • Chiorean EG, Von Hoff DD, Reni M, Arena FP, Infante JR, Bathini VG, Wood TE, Mainwaring PN, Muldoon RT, Clingan PR, Kunzmann V, Ramanathan RK, Tabernero J, Goldstein D, McGovern D, Lu B, Ko A. CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Ann Oncol. 2016 Apr;27(4):654-60. doi: 10.1093/annonc/mdw006. Epub 2016 Jan 22. PubMed 26802160 ↗
  • Goldstein D, Von Hoff DD, Moore M, Greeno E, Tortora G, Ramanathan RK, Macarulla T, Liu H, Pilot R, Ferrara S, Lu B. Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT). Eur J Cancer. 2016 Jan;52:85-91. doi: 10.1016/j.ejca.2015.10.017. Epub 2015 Dec 1. PubMed 26655559 ↗
  • Portal A, Pernot S, Tougeron D, Arbaud C, Bidault AT, de la Fouchardiere C, Hammel P, Lecomte T, Dreanic J, Coriat R, Bachet JB, Dubreuil O, Marthey L, Dahan L, Tchoundjeu B, Locher C, Lepere C, Bonnetain F, Taieb J. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. Br J Cancer. 2015 Sep 29;113(7):989-95. doi: 10.1038/bjc.2015.328. Epub 2015 Sep 15. PubMed 26372701 ↗
  • Goldstein D, El-Maraghi RH, Hammel P, Heinemann V, Kunzmann V, Sastre J, Scheithauer W, Siena S, Tabernero J, Teixeira L, Tortora G, Van Laethem JL, Young R, Penenberg DN, Lu B, Romano A, Von Hoff DD. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst. 2015 Jan 31;107(2):dju413. doi: 10.1093/jnci/dju413. Print 2015 Feb. PubMed 25638248 ↗
  • Vogel A, Pelzer U, Salah-Eddin AB, Koster W. First-line nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer from routine clinical practice. In Vivo. 2014 Nov-Dec;28(6):1135-40. PubMed 25398812 ↗
  • Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013 Oct 31;369(18):1691-703. doi: 10.1056/NEJMoa1304369. Epub 2013 Oct 16. PubMed 24131140 ↗
  • Von Hoff DD, Cridebring D, Tian OY, Han H, Bhore R, Franco T, Ondovik MS, Louis CU. Analysis of the Role of Plasma 25-Hydroxyvitamin D Levels in Survival Outcomes in Patients from the Phase III MPACT Trial of Metastatic Pancreatic Cancer. Oncologist. 2021 Apr;26(4):e704-e709. doi: 10.1002/onco.13645. Epub 2021 Jan 11. PubMed 33345430 ↗
  • McCleary-Wheeler AL, McWilliams R, Fernandez-Zapico ME. Aberrant signaling pathways in pancreatic cancer: a two compartment view. Mol Carcinog. 2012 Jan;51(1):25-39. doi: 10.1002/mc.20827. PubMed 22162229 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2009 to primary completion in Sep 2012, 42 months.

Results were first posted in Dec 2013, 1 year 2 months after primary completion.

Of 84 phase 3 interventional studies under Pancreatic Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 77. This study's 42 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2009
First posted
Feb 16, 2009
StartActual
Mar 1, 2009
Primary completionActual
Sep 17, 2012
CompletionActual
Apr 9, 2013
Results first posted
Dec 11, 2013
Last update
Nov 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00844649
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Feb 16, 2009
Start date
Mar 1, 2009
Primary completion
Sep 17, 2012
Completion
Apr 9, 2013
Results posted
Dec 11, 2013
Last update
Nov 25, 2019

Study contacts

Daniel Von Hoff, MD
principal investigator · Scottsdale Clinical Research Institute

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Albumin-Bound Paclitaxel

Start the discussion